Another potential mechanism of EGFR inhibitor resistance is inflammation, such as by release of the inflammatory cytokine prostaglandin E2, which in lung cancer cells induced phosphorylation of MAPK, indicating a bypass of EGFR activation (reviewed in [142]). Here, EGFR is linked to lung cancer.